Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
| Current Price | ₹131.05 |
|---|---|
| Market Cap | ₹731 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | -216.2 |
| Return on Equity | -1.20% |
| 52-Week Range | ₹50.93 – ₹141.38 |
| Beta (1Y) | 0.47 |
| Revenue | ₹115 Cr |
|---|---|
| Net Profit | ₹21 Cr |
| EPS (Basic) | ₹3.89 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Manufacturing of Chemicals Business-100%
Valiant Laboratories Limited is trading at ₹131.05, with a market capitalisation of ₹731 Cr.
Valiant Laboratories Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Valiant Laboratories Limited has a P/E of -216.2 and a return on equity of -1.20%.
In Q1 FY27, Valiant Laboratories Limited reported revenue of ₹115 Cr and net profit of ₹21 Cr, with basic EPS of ₹3.89 (consolidated, parsed from the company's exchange filing).